MedDataX Logo

Investigation of Genetic Risk of Atrial Fibrillation

NCT ID: NCT00412438

Last Updated: 2006-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The atrial fibrillation (AF) is the most common cardiac rhythm disturbance that is responsible for substantial morbidity and mortality independent of associated heart disease or other risk factors. Even in the absence of preexisting cardiovascular disease, AF remains significantly associated with excess mortality rates. The current unsatisfactory treatment for AF comes from lack of understanding of the pathophysiology of AF. The purpose of this study is to identify gene polymorphisms that confer susceptibility to atrial fibrillation. Patients with AF（N=500） and healthy volunteer（N=1000） without AF are enrolled in this study. Patients with coronary artery disease, severe valvular heart disease, cardiomyopathy or heart failure were excluded from the study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of atrial fibirillation

Exclusion Criteria

* coronary artery disease
* severe valvular heart disease
* cardiomyopathy
* heart failure
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nagoya University

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kenji Yasui, MD, Phd

Role: STUDY_CHAIR

Department of Bio-information Analysis, Research Institute of Enviromental Medicine, Nagoya University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Bio-information Analysis, Research Institute of Enviromental Medicine, Nagoya University

Nagoya, Aichi-ken, Japan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Japan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kenji Yasui, MD, PhD

Role: CONTACT

Phone: +81-52-788-6211

Email: [email protected]

Masaki Yamauchi, MD

Role: CONTACT

Phone: +81-52-788-6210

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kenji Yasui, MD, PhD

Role: primary

Masaki Yamauchi, MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RIEM-G-1

Identifier Type: -

Identifier Source: org_study_id